RNAi screens identify CHD4 as an essential gene in breast cancer growth

Carolina D'Alesio, Simona Punzi, Angelo Cicalese, Lorenzo Fornasari, Laura Furia, Laura Riva, Alessandro Carugo, Giuseppe Curigliano, Carmen Criscitiello, Giancarlo Pruneri, Pier Giuseppe Pelicci, Mario Romolo Faretta, Daniela Bossi, Luisa Maria Lanfrancone

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Epigenetic regulation plays an essential role in tumor development and epigenetic modifiers are considered optimal potential druggable candidates. In order to identify new breast cancer vulnerabilities and improve therapeutic chances for patients, we performed in vivo and in vitro shRNA screens in a human breast cancer cell model (MCF10DCIS.com cell line) using epigenetic libraries. Among the genes identified in our screening, we deeply investigated the role of Chromodomain Helicase DNA binding Protein 4 (CHD4) in breast cancer tumorigenesis. CHD4 silencing significantly reduced tumor growth in vivo and proliferation in vitro of MCF10DCIS.com cells. Similarly, in vivo breast cancer growth was decreased in a spontaneous mouse model of breast carcinoma (MMTV-NeuT system) and in metastatic patient-derived xenograft models. Conversely, no reduction in proliferative ability of non-transformed mammary epithelial cells (MCF10A) was detected. Moreover, we showed that CHD4 depletion arrests proliferation by inducing a G0/G1 block of cell cycle associated with up-regulation of CDKN1A (p21). These results highlight the relevance of genetic screens in the identification of tumor frailties and the role of CHD4 as a potential pharmacological target to inhibit breast cancer growth.

Original languageEnglish
Pages (from-to)80901-80915
Number of pages15
JournalOncotarget
Volume7
Issue number49
DOIs
Publication statusPublished - 2016

Fingerprint

Essential Genes
DNA-Binding Proteins
RNA Interference
Breast Neoplasms
Growth
Epigenomics
Neoplasms
Heterografts
Small Interfering RNA
Libraries
Cell Cycle
Carcinogenesis
Breast
Up-Regulation
Epithelial Cells
Pharmacology
Cell Line
Genes

Keywords

  • Breast cancer
  • CHD4
  • Epigenetic targets
  • In vivo murine and human models
  • RNAi screen

ASJC Scopus subject areas

  • Oncology

Cite this

RNAi screens identify CHD4 as an essential gene in breast cancer growth. / D'Alesio, Carolina; Punzi, Simona; Cicalese, Angelo; Fornasari, Lorenzo; Furia, Laura; Riva, Laura; Carugo, Alessandro; Curigliano, Giuseppe; Criscitiello, Carmen; Pruneri, Giancarlo; Pelicci, Pier Giuseppe; Faretta, Mario Romolo; Bossi, Daniela; Lanfrancone, Luisa Maria.

In: Oncotarget, Vol. 7, No. 49, 2016, p. 80901-80915.

Research output: Contribution to journalArticle

@article{74962e4d05894142933012fbc39bd611,
title = "RNAi screens identify CHD4 as an essential gene in breast cancer growth",
abstract = "Epigenetic regulation plays an essential role in tumor development and epigenetic modifiers are considered optimal potential druggable candidates. In order to identify new breast cancer vulnerabilities and improve therapeutic chances for patients, we performed in vivo and in vitro shRNA screens in a human breast cancer cell model (MCF10DCIS.com cell line) using epigenetic libraries. Among the genes identified in our screening, we deeply investigated the role of Chromodomain Helicase DNA binding Protein 4 (CHD4) in breast cancer tumorigenesis. CHD4 silencing significantly reduced tumor growth in vivo and proliferation in vitro of MCF10DCIS.com cells. Similarly, in vivo breast cancer growth was decreased in a spontaneous mouse model of breast carcinoma (MMTV-NeuT system) and in metastatic patient-derived xenograft models. Conversely, no reduction in proliferative ability of non-transformed mammary epithelial cells (MCF10A) was detected. Moreover, we showed that CHD4 depletion arrests proliferation by inducing a G0/G1 block of cell cycle associated with up-regulation of CDKN1A (p21). These results highlight the relevance of genetic screens in the identification of tumor frailties and the role of CHD4 as a potential pharmacological target to inhibit breast cancer growth.",
keywords = "Breast cancer, CHD4, Epigenetic targets, In vivo murine and human models, RNAi screen",
author = "Carolina D'Alesio and Simona Punzi and Angelo Cicalese and Lorenzo Fornasari and Laura Furia and Laura Riva and Alessandro Carugo and Giuseppe Curigliano and Carmen Criscitiello and Giancarlo Pruneri and Pelicci, {Pier Giuseppe} and Faretta, {Mario Romolo} and Daniela Bossi and Lanfrancone, {Luisa Maria}",
year = "2016",
doi = "10.18632/oncotarget.12646",
language = "English",
volume = "7",
pages = "80901--80915",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "49",

}

TY - JOUR

T1 - RNAi screens identify CHD4 as an essential gene in breast cancer growth

AU - D'Alesio, Carolina

AU - Punzi, Simona

AU - Cicalese, Angelo

AU - Fornasari, Lorenzo

AU - Furia, Laura

AU - Riva, Laura

AU - Carugo, Alessandro

AU - Curigliano, Giuseppe

AU - Criscitiello, Carmen

AU - Pruneri, Giancarlo

AU - Pelicci, Pier Giuseppe

AU - Faretta, Mario Romolo

AU - Bossi, Daniela

AU - Lanfrancone, Luisa Maria

PY - 2016

Y1 - 2016

N2 - Epigenetic regulation plays an essential role in tumor development and epigenetic modifiers are considered optimal potential druggable candidates. In order to identify new breast cancer vulnerabilities and improve therapeutic chances for patients, we performed in vivo and in vitro shRNA screens in a human breast cancer cell model (MCF10DCIS.com cell line) using epigenetic libraries. Among the genes identified in our screening, we deeply investigated the role of Chromodomain Helicase DNA binding Protein 4 (CHD4) in breast cancer tumorigenesis. CHD4 silencing significantly reduced tumor growth in vivo and proliferation in vitro of MCF10DCIS.com cells. Similarly, in vivo breast cancer growth was decreased in a spontaneous mouse model of breast carcinoma (MMTV-NeuT system) and in metastatic patient-derived xenograft models. Conversely, no reduction in proliferative ability of non-transformed mammary epithelial cells (MCF10A) was detected. Moreover, we showed that CHD4 depletion arrests proliferation by inducing a G0/G1 block of cell cycle associated with up-regulation of CDKN1A (p21). These results highlight the relevance of genetic screens in the identification of tumor frailties and the role of CHD4 as a potential pharmacological target to inhibit breast cancer growth.

AB - Epigenetic regulation plays an essential role in tumor development and epigenetic modifiers are considered optimal potential druggable candidates. In order to identify new breast cancer vulnerabilities and improve therapeutic chances for patients, we performed in vivo and in vitro shRNA screens in a human breast cancer cell model (MCF10DCIS.com cell line) using epigenetic libraries. Among the genes identified in our screening, we deeply investigated the role of Chromodomain Helicase DNA binding Protein 4 (CHD4) in breast cancer tumorigenesis. CHD4 silencing significantly reduced tumor growth in vivo and proliferation in vitro of MCF10DCIS.com cells. Similarly, in vivo breast cancer growth was decreased in a spontaneous mouse model of breast carcinoma (MMTV-NeuT system) and in metastatic patient-derived xenograft models. Conversely, no reduction in proliferative ability of non-transformed mammary epithelial cells (MCF10A) was detected. Moreover, we showed that CHD4 depletion arrests proliferation by inducing a G0/G1 block of cell cycle associated with up-regulation of CDKN1A (p21). These results highlight the relevance of genetic screens in the identification of tumor frailties and the role of CHD4 as a potential pharmacological target to inhibit breast cancer growth.

KW - Breast cancer

KW - CHD4

KW - Epigenetic targets

KW - In vivo murine and human models

KW - RNAi screen

UR - http://www.scopus.com/inward/record.url?scp=85000949434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85000949434&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.12646

DO - 10.18632/oncotarget.12646

M3 - Article

AN - SCOPUS:85000949434

VL - 7

SP - 80901

EP - 80915

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 49

ER -